Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 579 of 6351
-
Could a zapping the gut help beat immunotherapy resistance?
Disease control Recruiting nowPreclinical and clinical evidence suggests that intestinal low-dose radiotherapy (ILDR) may enhance antitumor immune responses by modulating the gut microenvironment, thereby improving the efficacy of immune checkpoint inhibitors (ICBs) in refractory solid tumors. Based on these …
Phase 2 • Sponsor: Chuangzhen Chen • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Could a cystic fibrosis drug help brain bleed survivors walk again?
Disease control Recruiting nowSubarachnoid hemorrhage due to aneurysm rupture (SAH) results in high mortality, while survivors frequently suffer reduced quality of life and even loss of autonomy, particularly in the active population. A significant proportion of this morbidity and mortality is linked to the o…
Phase 2 • Sponsor: Fondation Ophtalmologique Adolphe de Rothschild • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New hope for older AML patients: shorter, safer transplant strategy
Disease control Recruiting nowThis phase II trial tests the safety, side effects, and how well combination chemotherapy with fludarabine, high-dose cytarabine, granulocyte colony-stimulating factor (G-CSF), and idarubicin (FLAG-Ida) followed immediately by reduced-intensity total body radiation therapy, calle…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Pulse radiation may supercharge immunotherapy against cancer
Disease control Recruiting nowThe goal of this clinical trial is to find out whether Adaptive Pulse Radiotherapy (Pulse RT) combined with immune checkpoint inhibitors (ICIs) helps treat advanced solid tumors. It will also check how safe this combined treatment is and how it affects the immune system and qual…
Phase 2 • Sponsor: Samsung Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New hope for kidney cancer: drug combo targets tumors after immunotherapy fails
Disease control Not yet recruitingThis study is a multicenter, open-label, randomized controlled trial that enrolled 116 patients with advanced or metastatic renal cell carcinoma who had failed first-line treatment with PD-1/PD-L1 monotherapy or VEGFR TKI combined with PD-1/PD-L1 therapy. Patients were randomly a…
Phase 3 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Jun 26, 2026 16:48 UTC
-
Brain bleed breakthrough? new device flushes blood away
Disease control Recruiting nowThe study is a multi-center prospective cohort, controlled, phase 4 post-market registry evaluating the efficacy and radiographic outcomes associated with the use of the IRRAflow® Active Fluid Exchange System compared to standard of care external ventricular drains.
Sponsor: Christopher P Kellner • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Gene therapy injection aims to halt rare blindness
Disease control Recruiting nowThe goal of this clinical trial is to learn if drug OPGx-BEST1 works to treat BVMD and ARB Bestrophinopathy. It will also learn about the safety of drug OPGx-BEST1. The main questions it aims to answer are: Evaluate the safety and tolerability of drug OPGx-BEST1 in one eye (the …
Phase 1/2 • Sponsor: Opus Genetics, Inc • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Supercharged immune cells take on tough kidney tumors
Disease control Recruiting nowTesting an investigational cancer therapy called TGFBR-2 KO CD70 CAR NK cell therapy.
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New drug combo shows promise in slowing advanced breast cancer
Disease control Recruiting nowThis is a prospective, randomised, controlled, multicentre study to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab (QL1706) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer.
Phase 2 • Sponsor: Wenjin Yin • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Could a diabetes pill help slow Alzheimer's? new study aims to find out.
Disease control Not yet recruitingAlzheimer's disease (AD) is a progressive neurodegenerative disease and a major global healthcare burden. Currently, the disease is only treated symptomatically and an effective disease-modifying therapy (DMT) that may slow the disease progression, and prevent cognitive and funct…
Phase 2 • Sponsor: Imperial College London • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New hope for advanced breast cancer: drug combo trial opens
Disease control Recruiting nowThis is a prospective, Phase II, open-label, two-arm parallel study evaluating the efficacy and safety of combined treatment (L-Ornithine L-Aspartate, N-Acetylcysteine) with CDK4/6 inhibitors and Fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer (ABC) …
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New transplant approach aims to fight blood cancers with fewer side effects
Disease control Recruiting nowThis is a phase I, prospective clinical trial studying the safety and feasibility of providing early memory T-cell DLI. The primary objective is: \- To assess the safety and feasibility of early CD45RA-depleted DLI administration. The secondary objectives are * To assess the …
Phase 1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Promising triple-drug combo aims to wipe out aggressive breast cancer before surgery
Disease control Recruiting nowThis study is a prospective, single arm, multi-center phase II clinical trial. The primary study objective is to evaluate the pathologic complete response(PCR) of treatment of TNBC breast cancer with neoadjuvant chemotherapy combined with Sintilimab and Bevacizumab , including th…
Phase 2 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New combo therapy aims to turn inoperable liver cancer into surgical candidates
Disease control Recruiting nowStudy Design: This is a pilot study with a single arm in a single centre assessing safety and efficacy of durvalumab in combination with bevacizumab and HAIC followed by SBRT. This study will be conducted in selected patients with intermediate or advanced stage HCC not amenable …
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New antibody injection could shrink nasal polyps and ease breathing
Disease control Recruiting nowTQC2731 injection is a humanized monoclonal antibody that targets Thymic Stromal Lymphopoietin (TSLP), blocks the TSLP pathway, and inhibits the production of downstream cytokines, thereby exerting anti-inflammatory effects. The purpose of this study is to evaluate the efficacy a…
Phase 3 • Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Promising drug cocktail targets tough blood cancers in kids
Disease control Recruiting nowTo learn if giving the study drugs calaspargase pegol-mknl and decitabine in combination with venetoclax can help to control relapsed/refractory T-ALL and T-LLy. The safety of this drug combination will also be studied.
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Could immunotherapy replace chemo in nasopharyngeal cancer?
Disease control Not yet recruitingThis phase III trial aims to evaluate the efficacy and safety of induction chemotherapy combined with serplulimab (induction/maintenance therapy) with omission of concurrent chemotherapy in patients with locally advanced nasopharyngeal carcinoma (LA-NPC).
Phase 3 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 26, 2026 18:11 UTC
-
New combo therapy aims to tame deadly transplant complication
Disease control Recruiting nowThis is a prospective, multicenter, randomized controlled trial designed to evaluate whether the combination of ruxolitinib and etanercept provides superior efficacy compared with ruxolitinib monotherapy in patients with severe corticosteroid-refractory acute graft-versus-host di…
Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New lupus drug candidate enters human trials
Disease control Recruiting nowThis study will evaluate the effect and safety of 626 in patients with SLE
Phase 1/2 • Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Penicillin shots tested to stop syphilis in pregnancy
Prevention Recruiting nowThe goal of this clinical trial is to learn if benzathine penicillin works to prevent maternal syphilis. It will also learn about the safety of benzathine penicillin. The main questions it aims to answer are: * Does benzathine penicillin lower the rate of syphilis in pregnancy? …
Phase 2 • Sponsor: University of California, Los Angeles • Aim: Prevention
Last updated Jun 27, 2026 13:00 UTC